<DOC>
	<DOCNO>NCT00851721</DOCNO>
	<brief_summary>The purpose study determine efficacy , safety , health-related quality life benefit FEIBA NF prophylactic treatment compare on-demand treatment .</brief_summary>
	<brief_title>Efficacy Safety Study Prophylactic Versus On-Demand Treatment With Feiba NF Subjects With Hemophilia A B High Titer Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Signed date informed consent form participant participant 's legally authorize representative The participant ≥ 4 ≤ 65 year age The participant Karnofsky performance score ≥ 60 Hemophilia A B severity , document history hightiter inhibitor ( &gt; 5 Bethesda unit ( BU ) ) least 12 month ; , inhibitor titer ≤ 5 BU , participant refractory increase dose either factor VIII ( FVIII ) factor IX ( FIX ) , demonstrate participant 's medical history Currently treat ondemand basis treatment bleed episode Adequate venous access , without central venous device ≥ 12 bleed episode require treatment bypass agent past 12 month , base medical history Competent inhome treatment infusion therapy Currently use bypass agent ( activated prothrombin complex concentrate ( APCC ) recombinant activate factor VII ( rFVIIa ) ) treatment bleed episode HCV , either antibody test polymerase chain reaction ( PCR ) ; HCV+ stable hepatic disease HIV , HIV+ stable disease CD4 count &gt; 200 cells/mm3 screen Female participant childbearing potential , present negative serum pregnancy test , agree employ adequate birth control measure duration study Currently receive immune tolerance induction ( ITI ) Currently regular prophylactic therapy prevent bleed episode Clinically symptomatic liver disease ( e.g . diagnosis cirrhosis [ confirm liver biopsy ] , portal vein hypertension , ascites , prothrombin time ( PT ) 5 second upper limit normal ) Platelet count &lt; 100,000/ml Planned elective surgery participation study Participant currently participate another clinical study receive investigational product device within 30 day prior study entry Planned use pegylated nonpegylated alphainterferon without ribavirin HCV infect participant plan use protease inhibitor HIV infect participant . Participants currently take medication 30day course eligible . Clinically significant increase Ddimer level historical baseline and/or associate chronic liver disease clinically evident thromboembolic event Known hypersensitivity antiinhibitor coagulant complex ( AICCs ) Currently treat systemic immunomodulating drug Prior history thromboembolic event : acute myocardial infarction , deep vein thrombosis , pulmonary embolism Diagnosis advance atherosclerosis , malignancy and/or disease may increase participant 's risk thromboembolic complication Clinically significant medical , psychiatric , cognitive illness , recreational drug/alcohol use , opinion investigator , would affect participant safety compliance</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Factor VIII Inhibitor</keyword>
	<keyword>Factor IX Inhibitor</keyword>
	<keyword>Hemophilia B</keyword>
</DOC>